US Regulatory Update -- Tykerb(R) (lapatinib)

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to dif...

Full description

Saved in:
Bibliographic Details
Published inM2 Presswire
Format Newsletter
LanguageEnglish
Published Coventry Normans Media Ltd 13.07.2012
Subjects
Safe harbor
Online AccessGet full text

Cover

More Information
Summary:Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.